By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
VKTX is a high-risk, high-reward play on obesity treatment, with Phase 3 data for VK2735 being crucial. Success is not guaranteed due to intense competition, potential safety signals, and cash runway concerns.
Risk: Failure to demonstrate superior efficacy and durability in Phase 3 trials, along with potential safety signals and cash runway issues.
Opportunity: Potential acquisition by Big Pharma if VK2735 proves non-inferior in Phase 3 trials.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Shares of Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biotech, have moved in exactly the wrong direction this year, down 8% to date. However, the drugmaker has important catalysts on the horizon that could make the stock a bargain at its current price of $32 per share. Should investors initiate positions today?
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
Viking Therapeutics is developing medicines for chronic weight management. The company's leading candidate, subcutaneous VK2735, is currently in phase 3 studies. We should see data from these trials next year. On the one hand, subcutaneous VK2735 posted strong phase 2 results, and if it can repeat that performance in its ongoing clinical trials, Viking Therapeutics' shares will soar.
Further, the biotech has other promising candidates, including an oral formulation of VK2735 for which it could start late-stage studies by year-end. That said, the anti-obesity landscape has evolved since Viking Therapeutics revealed phase 2 clinical trial data for subcutaneous VK2735. And there will be more progress -- including more phase 2 and phase 3 assets that will complete clinical trials -- over the next year or so.
That means the bar to impress Wall Street is now higher. That's not surprising: given that the weight-loss field is projected to grow rapidly over the coming decade, many pharmaceutical leaders are looking to carve out a niche. Where does that leave Viking Therapeutics? The stock is an intriguing -- albeit fairly risky -- way to try to capitalize on this growing therapeutic area.
Provided VK2735 can post solid phase 2 and phase 3 results across both formulations, the biotech's shares will soar, arguably making it a bargain at current levels. But the company could just as well lose significant value over the next five years if it encounters setbacks. Investors comfortable with the risk and volatility should consider initiating a small position. Everyone else will want to look elsewhere.
Before you buy stock in Viking Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Viking Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $417,305! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,293,148!
Now, it’s worth noting Stock Advisor’s total average return is 936% — a market-crushing outperformance compared to 209% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of June 23, 2026. *
Prosper Junior Bakiny has positions in Viking Therapeutics. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"The most important risk is that VK2735 fails to deliver meaningful, durable efficacy or encounters safety and commercialization hurdles, keeping upside capped despite the current price."
VKTX is a high‑risk, high‑variance bet on one lead asset in a crowded obesity landscape. The article hinges on Phase 3 VK2735 data next year and possible late-stage trials for an oral form, but the path to meaningful revenue remains long and uncertain. Even with clean Phase 2 signals, many obesity assets stumble in Phase 3 or run into safety, tolerability, or dosing issues that depress uptake and payer coverage. Competitive intensity, pricing pressure on weight-loss therapies, and the need for substantial capital to fund trials and commercialization could keep the stock volatile and potentially underperform longer‑dated expectations baked into a $32 share price. Dilution risk lurking if cash runs low.
Strong Phase 3 data could still disappoint on safety or durability, and even good results may not translate into rapid adoption or a favorable payer environment.
"Viking Therapeutics is currently a speculative M&A target where the valuation ceiling is capped by the clinical 'best-in-class' requirement in an increasingly crowded weight-loss market."
Viking Therapeutics (VKTX) is currently priced as a binary outcome play on VK2735. While the phase 2 data was impressive, the article glosses over the brutal reality of the GLP-1/GIP receptor agonist arms race. VKTX is not just competing against Eli Lilly and Novo Nordisk, but a wave of next-gen oral small molecules and multi-agonist peptides from Amgen and Roche. At a ~$6 billion market cap, the stock is pricing in a successful commercialization path, yet it lacks the manufacturing scale or the established distribution moat of the incumbents. Investors are essentially betting on a buyout premium, which may evaporate if clinical data doesn't provide a clear 'best-in-class' efficacy profile.
Viking's oral formulation could offer a superior side-effect profile or dosing convenience that captures significant market share even if it isn't the absolute most potent drug on the market.
"VKTX's phase 3 bar is now set by Novo/Lilly's real-world data, not by its own phase 2 results, and the article fails to quantify what 'solid results' must mean to move the needle."
The article frames VKTX as a 'bargain' on phase 3 catalysts, but omits critical context: the GLP-1 competitive landscape has shifted dramatically since VK2735's phase 2 data. Novo Nordisk (NVO) and Eli Lilly (LLY) have already demonstrated superior efficacy and durability in real-world use. VKTX's dual GLP-1/GCG agonist is theoretically differentiated, but phase 3 must not just match — it must *exceed* existing standards to justify a premium valuation. The article's 'bargain at $32' claim ignores that biotech risk premiums have compressed; clinical-stage obesity plays now trade on probability-adjusted peak sales, not optionality. Execution risk is severe.
If VK2735 demonstrates superior weight loss durability or tolerability versus Ozempic/Mounjaro in phase 3, VKTX could command a meaningful partnership or acquisition premium — making $32 genuinely cheap on a risk-adjusted basis.
"Intense competition from approved GLP-1 therapies and Viking’s lack of late-stage differentiation make the risk/reward unattractive at current levels."
The article frames VKTX as a high-upside obesity play at $32 if subcutaneous and oral VK2735 clear phase 3, yet it understates how quickly the bar has risen. Approved GLP-1s from Novo Nordisk and Eli Lilly already deliver 15-20% weight loss with cardiovascular outcomes data and massive scale advantages. Viking remains a pure clinical-stage name with no revenue, no approved products, and an oral candidate still pre-phase 3. Any delay, safety signal, or merely “good but not superior” readout next year will likely trigger sharp downside given the crowded pipeline and limited cash runway typical for this sector.
Phase 2 data already showed competitive weight-loss efficacy and tolerability; if phase 3 simply replicates those numbers without major setbacks, VKTX could still rerate sharply on first-mover potential in the oral segment.
"Durability, safety signals, payer adoption, and dilution risk can cap upside even if VK2735 clears phase 3, so the current ~$32 may overprice resilience."
Claude is right that phase 3 must exceed current standards, but the risk isn't just efficacy—it's durability, safety signals, and real-world payer hurdles that could erode value even with a best-in-class readout. The stock's $32 today already prices in a lot of binary upside; delay or a modest safety signal could trigger sharp re-rating. Cash runway and potential dilution remain underappreciated risks that could squeeze the upside.
"Viking's value is driven by its scarcity as a late-stage acquisition target rather than its ability to beat incumbents on pure efficacy."
Claude and Grok are fixated on the 'best-in-class' efficacy trap, but you're all ignoring the M&A endgame. Big Pharma doesn't buy VKTX for a 'superior' drug; they buy it to acquire a de-risked asset that solves their own supply chain bottlenecks. If VK2735 proves non-inferior, it becomes a plug-and-play revenue stream for a major player struggling with LLY/NVO's dominance. The valuation isn't about market share; it's about the scarcity of viable, late-stage obesity assets.
"M&A premium requires either regulatory approval or Phase 3 superiority—neither is guaranteed, and 'supply chain relief' alone doesn't justify a $6B acquisition of an unproven asset."
Gemini's M&A thesis is underexplored but rests on a shaky assumption: Big Pharma acquires de-risked assets, not Phase 3 candidates. VKTX remains clinical-stage with unproven manufacturing and no approved product. The 'supply chain bottleneck' angle assumes LLY/NVO can't scale—they can. M&A premium only materializes post-approval or with Phase 3 data that materially outperforms incumbents. Without that, VKTX is a liability, not a shortcut.
"Even non-inferior oral data won't trigger M&A without proven manufacturing scale and extended cash runway."
Gemini's M&A plug-and-play narrative assumes non-inferior data alone unlocks buyer interest, yet ignores that oral small molecules still face formulation scale-up and stability hurdles that injectables from LLY and NVO have already solved. Claude flags the post-approval timing correctly, but the real gap is whether Viking's cash runway survives another 18 months of phase 3 without forcing a dilutive raise that caps any premium.
VKTX is a high-risk, high-reward play on obesity treatment, with Phase 3 data for VK2735 being crucial. Success is not guaranteed due to intense competition, potential safety signals, and cash runway concerns.
Potential acquisition by Big Pharma if VK2735 proves non-inferior in Phase 3 trials.
Failure to demonstrate superior efficacy and durability in Phase 3 trials, along with potential safety signals and cash runway issues.